CN114533761A - 治疗视网膜疾病的方法 - Google Patents

治疗视网膜疾病的方法 Download PDF

Info

Publication number
CN114533761A
CN114533761A CN202210141757.7A CN202210141757A CN114533761A CN 114533761 A CN114533761 A CN 114533761A CN 202210141757 A CN202210141757 A CN 202210141757A CN 114533761 A CN114533761 A CN 114533761A
Authority
CN
China
Prior art keywords
cells
subject
rpe
retinal
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210141757.7A
Other languages
English (en)
Chinese (zh)
Inventor
E·班宁
B·E·鲁宾奥夫
O·博哈纳-卡什坦
N·内泽尔
C·S·欧文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Cure Neurosciences Ltd
Original Assignee
Cell Cure Neurosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56284392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN114533761(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cell Cure Neurosciences Ltd filed Critical Cell Cure Neurosciences Ltd
Publication of CN114533761A publication Critical patent/CN114533761A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00727—Apparatus for retinal reattachment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Surgery (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202210141757.7A 2014-12-30 2015-04-30 治疗视网膜疾病的方法 Pending CN114533761A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201462097753P 2014-12-30 2014-12-30
US62/097,753 2014-12-30
US201562116972P 2015-02-17 2015-02-17
US201562116980P 2015-02-17 2015-02-17
US62/116,972 2015-02-17
US62/116,980 2015-02-17
PCT/IL2015/050456 WO2016108219A1 (en) 2014-12-30 2015-04-30 Methods of treating retinal diseases
CN201580076318.0A CN107427534A (zh) 2014-12-30 2015-04-30 治疗视网膜疾病的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580076318.0A Division CN107427534A (zh) 2014-12-30 2015-04-30 治疗视网膜疾病的方法

Publications (1)

Publication Number Publication Date
CN114533761A true CN114533761A (zh) 2022-05-27

Family

ID=56284392

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210141757.7A Pending CN114533761A (zh) 2014-12-30 2015-04-30 治疗视网膜疾病的方法
CN201580076318.0A Pending CN107427534A (zh) 2014-12-30 2015-04-30 治疗视网膜疾病的方法
CN202210144880.4A Pending CN114469998A (zh) 2014-12-30 2015-04-30 治疗视网膜疾病的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201580076318.0A Pending CN107427534A (zh) 2014-12-30 2015-04-30 治疗视网膜疾病的方法
CN202210144880.4A Pending CN114469998A (zh) 2014-12-30 2015-04-30 治疗视网膜疾病的方法

Country Status (18)

Country Link
US (2) US20180008458A1 (enExample)
EP (1) EP3240612B1 (enExample)
JP (4) JP2018501281A (enExample)
KR (2) KR102359257B1 (enExample)
CN (3) CN114533761A (enExample)
AU (3) AU2015373111B2 (enExample)
BR (1) BR112017014332A2 (enExample)
CA (2) CA3175175A1 (enExample)
DK (1) DK3240612T3 (enExample)
EA (1) EA201791518A1 (enExample)
ES (1) ES2843626T3 (enExample)
HK (1) HK1246179A1 (enExample)
IL (1) IL253244B2 (enExample)
MX (1) MX2017008818A (enExample)
PH (1) PH12017501217A1 (enExample)
SG (1) SG11201705378RA (enExample)
WO (1) WO2016108219A1 (enExample)
ZA (1) ZA201704359B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114469998A (zh) * 2014-12-30 2022-05-13 细胞治疗神经科学有限公司 治疗视网膜疾病的方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
KR20170115514A (ko) 2014-12-30 2017-10-17 셀 큐어 뉴로사이언시스 리미티드 Rpe 세포 집단 및 이를 생성하는 방법
EP3916085A1 (en) 2014-12-30 2021-12-01 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
ES2865024T3 (es) 2015-07-29 2021-10-14 Hadasit Med Res Service Producción a gran escala de células de epitelio pigmentario retiniano
US11090337B2 (en) 2015-08-05 2021-08-17 Cell Cure Neurosciences Ltd Preparation of photoreceptors for the treatment of retinal diseases
WO2017021973A1 (en) 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
KR20200031559A (ko) 2017-03-16 2020-03-24 리니지 셀 테라퓨틱스, 인크. 망막 질환 요법의 치료 효과를 측정하는 방법
EP3661529A1 (en) 2017-07-31 2020-06-10 Lineage Cell Therapeutics, Inc. Compositions and methods for restoring or preventing loss of vision caused by disease or traumatic injury
KR102725720B1 (ko) * 2017-12-29 2024-11-06 셀 큐어 뉴로사이언시스 리미티드 망막 색소 상피 세포 조성물
CA3097428A1 (en) 2018-04-20 2019-10-24 FUJIFILM Cellular Dynamics, Inc. Method for differentiation of ocular cells and use thereof
CN108795864B (zh) * 2018-05-24 2021-08-24 中山大学中山眼科中心 一种利用人诱导多能干细胞获得富含视锥及视杆细胞的类视网膜组织的方法
US10264436B1 (en) * 2018-05-29 2019-04-16 Link Labs, Inc. BLE networking systems and methods providing central and peripheral role reversal with independent peripheral network connectivity
CA3110563A1 (en) * 2018-08-31 2020-03-05 University Of Florida Research Foundation, Incorporated Adeno-associated viral vectors for the treatment of best disease
CN113811605B (zh) * 2019-05-15 2024-09-27 诺和诺德股份有限公司 从人多能干细胞获得眼野祖细胞的方法
IL298569A (en) * 2020-05-25 2023-01-01 Lineage Cell Therapeutics Inc Methods and compositions for treating retinal diseases and conditions
EP3964227A1 (en) * 2020-09-08 2022-03-09 Curebiotec GmbH Method for the treatment of a disease using pigment epithelium-derived factor (pedf)
IL301042A (en) * 2020-09-03 2023-05-01 Curebiotec Gmbh Pigment epithelium-derived factor (pedf) for use in treatment of macular degeneration or choroidal neovascularisation
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115137553A (zh) * 2022-07-11 2022-10-04 上海市同济医院 一种免造孔视网膜下液排出装置
CN115212233B (zh) * 2022-08-26 2024-05-28 北京市眼科研究所 用于治疗视网膜相关疾病的组合物、试剂盒及其应用
WO2024110625A1 (en) * 2022-11-24 2024-05-30 Universität Bern Cralbp based therapeutics for retinal disorders
KR102531735B1 (ko) * 2022-12-27 2023-05-12 주식회사 셀리코 초소형 자극기 및 이의 제조방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CN101688178B (zh) 2007-04-18 2013-12-04 哈达锡特医学研究服务及发展有限公司 干细胞衍生的视网膜色素上皮细胞
DK2209888T3 (da) * 2007-10-12 2020-01-20 Astellas Inst For Regenerative Medicine Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler
KR101025880B1 (ko) * 2008-10-23 2011-03-30 공희숙 성체 줄기세포를 이용한 인슐린 분비세포로의 분화 유도방법
WO2011063005A2 (en) * 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
WO2013074681A1 (en) * 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Pharmaceutical preparations of human rpe cells and uses thereof
US9850463B2 (en) * 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
WO2013154336A1 (ko) * 2012-04-09 2013-10-17 연세대학교 산학협력단 망막하 주사 또는 추출용 중공형 마이크로니들 및 망막하 주사기
US20150368713A1 (en) * 2013-02-01 2015-12-24 THE UNITED STATES OF AMERICAN, as represented by the Secretary, Department of Health and Human Serv METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
CN105814194A (zh) * 2013-12-11 2016-07-27 辉瑞有限公司 产生视网膜色素上皮细胞的方法
KR20170115514A (ko) 2014-12-30 2017-10-17 셀 큐어 뉴로사이언시스 리미티드 Rpe 세포 집단 및 이를 생성하는 방법
MX2017008818A (es) 2014-12-30 2018-03-14 Cell Cure Neurosciences Ltd Metodos para tratar enfermedades de la retina.
EP3916085A1 (en) 2014-12-30 2021-12-01 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
KR101982801B1 (ko) * 2015-10-28 2019-05-30 서울대학교 산학협력단 망막색소상피 분화 유도용 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114469998A (zh) * 2014-12-30 2022-05-13 细胞治疗神经科学有限公司 治疗视网膜疾病的方法

Also Published As

Publication number Publication date
KR102359257B1 (ko) 2022-02-07
MX2017008818A (es) 2018-03-14
EA201791518A1 (ru) 2017-10-31
IL253244B1 (en) 2023-05-01
PH12017501217A1 (en) 2018-01-29
ES2843626T3 (es) 2021-07-19
US20180008458A1 (en) 2018-01-11
EP3240612A4 (en) 2018-06-13
US20230028133A1 (en) 2023-01-26
JP2020143137A (ja) 2020-09-10
ZA201704359B (en) 2018-08-29
AU2015373111A1 (en) 2017-07-13
DK3240612T3 (da) 2021-01-18
CA3175175A1 (en) 2016-07-07
BR112017014332A2 (pt) 2018-01-02
IL253244A0 (en) 2017-08-31
IL253244B2 (en) 2023-09-01
JP2018501281A (ja) 2018-01-18
KR20170120583A (ko) 2017-10-31
KR102514912B1 (ko) 2023-03-27
JP2024023611A (ja) 2024-02-21
CN114469998A (zh) 2022-05-13
CA2972700A1 (en) 2016-07-07
AU2023255009A1 (en) 2023-11-16
HK1246179A1 (zh) 2018-09-07
WO2016108219A1 (en) 2016-07-07
AU2021229196A1 (en) 2021-10-07
AU2015373111B2 (en) 2021-06-24
KR20220020422A (ko) 2022-02-18
JP2022125160A (ja) 2022-08-26
CN107427534A (zh) 2017-12-01
EP3240612B1 (en) 2020-12-23
EP3240612A1 (en) 2017-11-08
SG11201705378RA (en) 2017-08-30

Similar Documents

Publication Publication Date Title
US20230028133A1 (en) Methods of treating retinal diseases
US11987810B2 (en) RPE cell populations and methods of generating same
AU2023200036B2 (en) Assessing retinal pigment epithelial cell populations
JP2018531048A6 (ja) 網膜色素上皮細胞の調製法
JP2018531048A (ja) 網膜色素上皮細胞の調製法
HK40066083A (en) Methods of treating retinal diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination